Steroid-Refractory Chronic Graft-Versus-Host Disease: Treatment Options and Nursing Care

被引：0
|
作者：
Cazeau, Naomi [1 ]
Rodriguez, Stephany [2 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA
[2] Univ Calif San Francisco, Dept Hematol Blood & Marrow Transplant & Cellular, San Francisco, CA USA
来源：
CLINICAL JOURNAL OF ONCOLOGY NURSING | 2023年 / 27卷 / 03期
基金：
美国国家卫生研究院;
关键词：
stem cell transplantation; graft-versus-host disease; steroid-refractory GVHD; CONSENSUS DEVELOPMENT PROJECT; CLINICAL-TRIALS; CRITERIA; TRANSPLANTATION; FAILURE;
D O I：
10.1188/23.CJON.259-265
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
BACKGROUND: Chronic graft-versus-host disease (cGVHD) is a significant complication for patients who receive allogeneic hematopoietic stem cell transplantation. This disease is further complicated for patients who are refractory to steroids. This article reviews emerging therapies and supportive care for patients with steroid-refractory cGVHD.OBJECTIVES:This article provides foundational knowledge on steroid-refractory cGVHD, emerg-ing treatment options, and related supportive care.METHODS: Current research on emerging therapies for patients with steroid-refractory cGVHD is summarized along with supportive care recommendations and a review of related nursing considerations.FINDINGS: Emerging therapies for steroid -refractory cGVHD offer opportunities for improved clinical outcomes for these patients. Nursing knowledge of new therapies and supportive care for patients with steroid-refractory cGVHD supports the provision of optimal nursing care for a complex population of patients.
引用
收藏
页码：259 / 265
页数：7
相关论文
共 50 条
  • [21] Azacitidine for the treatment of steroid-refractory chronic graft-versus-host disease: the results of the phase II AZTEC clinical trial
    Malladi, Ram
    Ahmed, Ikhlaaq
    McIlroy, Graham
    Dignan, Fiona L.
    Protheroe, Rachel
    Jackson, Aimee
    Moss, Paul
    Nunnick, Jane
    Siddique, Shamyla
    Bishop, Rebecca
    Elhaneid, Mohamed
    Hodgkinson, Andrea
    Craddock, Charles
    BONE MARROW TRANSPLANTATION, 2021, 56 (12) : 2948 - 2955
  • [22] Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study
    Shiratori, Souichi
    Fukushima, Kentaro
    Onishi, Yasushi
    Doki, Noriko
    Goto, Tatsunori
    Okada, Masaya
    Nakamae, Hirohisa
    Maeda, Yoshinobu
    Kato, Koji
    Ishikawa, Takayuki
    Kondo, Tadakazu
    Toyosaki, Masako
    Ikeda, Takashi
    Uchida, Naoyuki
    Maki, Akio
    Shimada, Fumika
    Tajima, Takeshi
    Stefanelli, Tommaso
    Teshima, Takanori
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2024, 120 (06) : 705 - 716
  • [23] Long-term outcomes of ruxolitinib therapy in steroid-refractory graft-versus-host disease in children and adults
    Moiseev, I. S.
    Morozova, E., V
    Bykova, T. A.
    Paina, O., V
    Smirnova, A. G.
    Dotsenko, A. A.
    Borzenkova, E. S.
    Galimov, A. N.
    Gudognikova, Ya, V
    Ekushov, K. A.
    Kozhokar, P., V
    Osipova, A. A.
    Pirogova, O., V
    Rudakova, T. A.
    Klimova, O. U.
    Tcvetkov, N. Yu
    Kulagin, E. A.
    Surkova, E. A.
    Lapin, S., V
    Rodionov, G. G.
    Moiseev, S., I
    Serov, Yu A.
    Zubarovskaya, L. S.
    Afanasyev, B., V
    BONE MARROW TRANSPLANTATION, 2020, 55 (07) : 1379 - 1387
  • [24] Treatment and unmet needs in steroid-refractory acute graft-versus-host disease
    Malard, Florent
    Huang, Xiao-Jun
    Sim, Joycelyn P. Y.
    LEUKEMIA, 2020, 34 (05) : 1229 - 1240
  • [25] Ibrutinib for therapy of steroid-refractory chronic graft-versus-host disease: a multicenter real-world analysis
    Pidala, Joseph
    Kim, Jongphil
    Kalos, Denise
    Cutler, Corey
    Defilipp, Zachariah
    Flowers, Mary E. D.
    Hamilton, Betty K.
    Chin, Kuo-Kai
    Rotta, Marcello
    El Jurdi, Najla
    Hamadani, Mehdi
    Ahmed, Gulrayz
    Kitko, Carrie
    Ponce, Doris
    Sung, Anthony
    Tang, Helen
    Farhadfar, Nosha
    Nemecek, Eneida
    Pusic, Iskra
    Qayed, Muna
    Rangarajan, Hemalatha
    Hogan, William
    Etra, Aaron
    Jaglowski, Samantha
    BLOOD ADVANCES, 2025, 9 (05) : 1040 - 1048
  • [26] Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease
    Kaloyannidis, Panayotis
    Al Shaibani, Eshrak
    Apostolidis, Ioannis
    Kanfar, Solaf
    Al Anezi, Khalid
    Al Hashmi, Hani
    BONE MARROW TRANSPLANTATION, 2019, 54 (05) : 746 - 748
  • [27] Effect of ruxolitinib on the oral mucosa of patients with steroid-refractory chronic Graft-versus-Host disease and oral involvement
    Kaurinovic, Martina
    Delli, Konstantina
    Jonk, Ana-Mae E.
    Biswana, Anouschka
    Hazenberg, Carin L. E.
    Choi, Goda
    de Groot, Marco R.
    Morsink, Linde M.
    Vissink, Arjan
    Bellido, Mar
    CLINICAL ORAL INVESTIGATIONS, 2022, 26 (05) : 4209 - 4216
  • [28] Ruxolitinib for steroid-refractory graft-versus-host disease: A case series
    Lancman, Guido
    Coltoff, Alexander
    Steinberg, Amir
    HEMATOLOGICAL ONCOLOGY, 2018, 36 (03) : 611 - 613
  • [29] Ruxolitinib for chronic steroid-refractory graft versus host disease: a single center experience
    Xue, Elisabetta
    Lorentino, Francesca
    Pavesi, Francesca
    Assanelli, Andrea
    Peccatori, Jacopo
    Bernardi, Massimo
    Corti, Consuelo
    Ciceri, Fabio
    Stanghellini, Maria Teresa Lupo
    LEUKEMIA RESEARCH, 2021, 109
  • [30] Immunopathology and biology-based treatment of steroid-refractory graft-versus-host disease
    Toubai, Tomomi
    Magenau, John
    BLOOD, 2020, 136 (04) : 429 - 440
12345